News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nanobiotix Starts Clinical Trial with Lead Product NBTXR3


9/13/2011 10:27:02 AM

PARIS--(BUSINESS WIRE)--Nanobiotix, a company developing cancer novel nanotherapeutics, announced today that its lead compound NBTXR3 has received the formal authorization from the French Medicine Agency, AFSSAPS1, to start the first clinical trial2.

Read at BioSpace.com

comments powered by Disqus
   
Sarcoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES